Northwest Biotherapeutics, Inc.
NWBO
$0.26
-$0.0096-3.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.46% | -45.67% | -8.42% | 2.42% | -31.02% |
| Total Depreciation and Amortization | -0.60% | -4.02% | 1.16% | 2.18% | 19.95% |
| Total Amortization of Deferred Charges | -61.07% | 55.72% | 12.22% | -14.76% | 57.38% |
| Total Other Non-Cash Items | -40.96% | -26.66% | 3,829.17% | -110.87% | 23.58% |
| Change in Net Operating Assets | 205.56% | -45.10% | 356.54% | -74.60% | 165.33% |
| Cash from Operations | 53.33% | -145.12% | 49.17% | -30.56% | 26.84% |
| Capital Expenditure | -19.23% | 55.68% | 66.22% | -117.99% | 42.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -19.23% | 55.68% | 66.22% | -117.99% | 42.82% |
| Total Debt Issued | -41.46% | 155.45% | -51.85% | 40.85% | -33.31% |
| Total Debt Repaid | -58.90% | 52.37% | -222.09% | -- | -- |
| Issuance of Common Stock | 21.69% | -40.84% | 132.04% | 134.71% | 1,001.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -93.81% | 18.93% | 5.63% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -200.00% | -- | -100.00% | -87.28% |
| Cash from Financing | -26.40% | 37.19% | -32.20% | 41.81% | -16.16% |
| Foreign Exchange rate Adjustments | -145.54% | 212.69% | -18,447.06% | -101.86% | 190.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 179.06% | -1,417.24% | -85.61% | 14.49% | 108.86% |